![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ZSCAN29 |
Gene summary for ZSCAN29 |
![]() |
Gene information | Species | Human | Gene symbol | ZSCAN29 | Gene ID | 146050 |
Gene name | zinc finger and SCAN domain containing 29 | |
Gene Alias | ZNF690 | |
Cytomap | 15q15.3 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q05BJ4 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
146050 | ZSCAN29 | HCC1_Meng | Human | Liver | HCC | 1.86e-33 | 4.22e-02 | 0.0246 |
146050 | ZSCAN29 | HCC2_Meng | Human | Liver | HCC | 1.15e-08 | 6.26e-02 | 0.0107 |
146050 | ZSCAN29 | HCC1 | Human | Liver | HCC | 3.26e-04 | 2.30e+00 | 0.5336 |
146050 | ZSCAN29 | HCC2 | Human | Liver | HCC | 5.38e-12 | 2.95e+00 | 0.5341 |
146050 | ZSCAN29 | S015 | Human | Liver | HCC | 1.04e-02 | 1.21e-01 | 0.2375 |
146050 | ZSCAN29 | S016 | Human | Liver | HCC | 1.26e-06 | 2.14e-01 | 0.2243 |
146050 | ZSCAN29 | S027 | Human | Liver | HCC | 1.35e-04 | 4.57e-01 | 0.2446 |
146050 | ZSCAN29 | S028 | Human | Liver | HCC | 4.73e-18 | 5.09e-01 | 0.2503 |
146050 | ZSCAN29 | S029 | Human | Liver | HCC | 2.09e-09 | 3.21e-01 | 0.2581 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ZSCAN29 | SNV | Missense_Mutation | c.944G>A | p.Gly315Asp | p.G315D | Q8IWY8 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-BH-A1FJ-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
ZSCAN29 | SNV | Missense_Mutation | c.357G>T | p.Glu119Asp | p.E119D | Q8IWY8 | protein_coding | deleterious(0.05) | probably_damaging(0.956) | TCGA-BH-A1FN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
ZSCAN29 | SNV | Missense_Mutation | novel | c.2533C>A | p.Leu845Ile | p.L845I | Q8IWY8 | protein_coding | deleterious(0.01) | probably_damaging(0.932) | TCGA-E2-A1IG-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
ZSCAN29 | SNV | Missense_Mutation | novel | c.88G>A | p.Ala30Thr | p.A30T | Q8IWY8 | protein_coding | tolerated(0.21) | probably_damaging(0.997) | TCGA-PL-A8LY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ZSCAN29 | insertion | In_Frame_Ins | novel | c.2106_2107insTCTGCCTGCCTCGGCCTCCCAAAGTGCTGGGATTACAGGCAT | p.Gly702_Glu703insSerAlaCysLeuGlyLeuProLysCysTrpAspTyrArgHis | p.G702_E703insSACLGLPKCWDYRH | Q8IWY8 | protein_coding | TCGA-A2-A0ER-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | ||
ZSCAN29 | insertion | Frame_Shift_Ins | novel | c.742_743insCAAGAGC | p.Trp248SerfsTer6 | p.W248Sfs*6 | Q8IWY8 | protein_coding | TCGA-A8-A08Z-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | ||
ZSCAN29 | insertion | Frame_Shift_Ins | novel | c.741_742insCAAGTTCAAAGGTCTCCAGAAGAGCTATCGGAAAG | p.Trp248GlnfsTer95 | p.W248Qfs*95 | Q8IWY8 | protein_coding | TCGA-A8-A08Z-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | ||
ZSCAN29 | insertion | In_Frame_Ins | novel | c.2280_2281insGCCTCCCAAAGTGCTGGGATTACAGGCATGAGC | p.Lys760_Pro761insAlaSerGlnSerAlaGlyIleThrGlyMetSer | p.K760_P761insASQSAGITGMS | Q8IWY8 | protein_coding | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
ZSCAN29 | insertion | Frame_Shift_Ins | novel | c.1886_1887insTGCAACCTCTGCCTTCTGGGTTCAA | p.Leu630AlafsTer16 | p.L630Afs*16 | Q8IWY8 | protein_coding | TCGA-BH-A0B8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD | ||
ZSCAN29 | SNV | Missense_Mutation | c.23G>C | p.Arg8Thr | p.R8T | Q8IWY8 | protein_coding | deleterious(0.02) | benign(0.056) | TCGA-EK-A3GK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |